» Articles » PMID: 37630975

Overview About Oral Films in Mental Disorders

Overview
Publisher MDPI
Specialty Chemistry
Date 2023 Aug 26
PMID 37630975
Authors
Affiliations
Soon will be listed here.
Abstract

Mental disorders are increasing worldwide, and efforts have been developed by multidisciplinary research groups to combine knowledge from different areas such as psychology, neuroscience, medicine, and biotechnology to develop strategies and products to promote the prevention of mental disorders. Excessive antipsychotic consumption is a public health problem, and innovative strategies must be devised. The development of innovative and, if possible, natural products is one of the strategies to combat this public health problem. Oral films are recent delivery systems that have been developed with several advantages that should be applied in this area. This review intends to draw attention to these new dosage forms of drugs and bioactive molecules pertinent to the field of mental health prevention and therapy and to the need for regulatory guidelines to ensure their quality and safety. This is a critical overview about strengths, weaknesses, opportunities, and threats related to oral film implementation in mental disorder treatment.

Citing Articles

Bioequivalence of Aripiprazole Oral Soluble Films and Orally Disintegrating Tablets in Healthy Participants: A Crossover Study.

Li R, Yang S, Yang G, Gu X, Zhang Z, Wang T Clin Transl Sci. 2025; 18(2):e70142.

PMID: 39937655 PMC: 11817677. DOI: 10.1111/cts.70142.

References
1.
McClellan C, Fingar K, Ali M, Olesiuk W, Mutter R, Gibson T . Price elasticity of demand for buprenorphine/naloxone prescriptions. J Subst Abuse Treat. 2019; 106:4-11. DOI: 10.1016/j.jsat.2019.08.001. View

2.
Ferlak J, Guzenda W, Osmalek T . Orodispersible Films-Current State of the Art, Limitations, Advances and Future Perspectives. Pharmaceutics. 2023; 15(2). PMC: 9965071. DOI: 10.3390/pharmaceutics15020361. View

3.
Cummings J, Lee G, Ritter A, Zhong K . Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018; 4:195-214. PMC: 6021548. DOI: 10.1016/j.trci.2018.03.009. View

4.
. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022; 9(2):137-150. PMC: 8776563. DOI: 10.1016/S2215-0366(21)00395-3. View

5.
Cilurzo F, Musazzi U, Franze S, Selmin F, Minghetti P . Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements. Drug Discov Today. 2017; 23(2):251-259. DOI: 10.1016/j.drudis.2017.10.003. View